|
MaxCyte Inc on Tuesday announced a higher revenue for 2022, and said it anticipates revenue to grow further during 2023. The Maryland, US-based commercial cell-engineering company with an office in Cheshire, England will release its annual results next week Wednesday. For the fourth quarter of 2022, MaxCyte anticipates growth of around 22% to about $12.4 million from $10.2 million. Meanwhile, for 2022 as a whole, it expects a 31% climb to $44.3 million from $33.9 million. Further, for 2023, the company expects revenue growth between 21% and 26% and strategic platform license programme-related revenue of around $6 million, compared to around $4.6 million in 2022. ‘Our diverse and robust partnership portfolio continues to grow with three new partnerships added in 2022, in addition to the signing of a partnership with Vertex Pharmaceuticals following the transfer from CRISPR Therapeutics for the development of its CRISPR/Cas9-based gene-edited therapy,’ said Chief Executive Officer Doug Doerfler. The company made no mention of profit or loss expectations. In 2021, it had a net loss of $19.1 million, widened 62% from $11.8 million in 2020. MaxCyte shares were 5.0% lower at 370.50 pence each in London on Tuesday morning. Copyright 2023 Alliance News Ltd. All Rights Reserved.
|
